{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:18:44Z","timestamp":1777605524143,"version":"3.51.4"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":4524,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart failure (HF), such as the renin\u2013angiotensin\u2013aldosterone system (RAAS), potentially beneficial counter-regulatory systems are also active in HF. These promote vasodilatation and natriuresis, inhibit abnormal growth, suppress the RAAS and sympathetic nervous system, and augment parasympathetic activity. The best understood of these mediators are the natriuretic peptides which are metabolized by the enzyme neprilysin. LCZ696 belongs to a new class of drugs, the angiotensin receptor neprilysin inhibitors (ARNIs), which both block the RAAS and augment natriuretic peptides.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with chronic HF, NYHA class II\u2013IV symptoms, an elevated plasma BNP or NT-proBNP level, and an LVEF of \u226440% were enrolled in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortailty and morbidity in Heart Failure trial (PARADIGM-HF). Patients entered a single-blind enalapril run-in period (titrated to 10 mg b.i.d.), followed by an LCZ696 run-in period (100 mg titrated to 200 mg b.i.d.). A total of 8436 patients tolerating both periods were randomized 1:1 to either enalapril 10 mg b.i.d. or LCZ696 200 mg b.i.d. The primary outcome is the composite of cardiovascular death or HF hospitalization, although the trial is powered to detect a 15% relative risk reduction in cardiovascular death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Perspectives<\/jats:title>\n                    <jats:p>PARADIGM-HF will determine the place of the ARNI LCZ696 as an alternative to enalapril in patients with systolic HF. PARADIGM-HF may change our approach to neurohormonal modulation in HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT01035255<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hft052","type":"journal-article","created":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T00:02:23Z","timestamp":1365206543000},"page":"1062-1073","source":"Crossref","is-referenced-by-count":386,"title":["Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)"],"prefix":"10.1093","volume":"15","author":[{"given":"John J. V.","family":"McMurray","sequence":"first","affiliation":[{"name":"BHF Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Cardiovascular Medicine , MA ,","place":["USA"]}]},{"given":"Jim","family":"Gong","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation , East Hanover, NJ ,","place":["USA"]}]},{"given":"Martin P.","family":"Lefkowitz","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation , East Hanover, NJ ,","place":["USA"]}]},{"given":"Adel R.","family":"Rizkala","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation , East Hanover, NJ ,","place":["USA"]}]},{"given":"Jean","family":"Rouleau","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montr\u00e9al, Institut de Cardiologie , Montr\u00e9al ,","place":["Canada"]}]},{"given":"Victor C.","family":"Shi","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation , East Hanover, NJ ,","place":["USA"]}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Cardiovascular Medicine , MA ,","place":["USA"]}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[{"name":"University of Gothenburg, Cardiovascular Medicine Department , Gothenburg ,","place":["Sweden"]}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[{"name":"The Medical University of South Carolina and RHJ Department of Veterans Administration Medical center , Charleston, SC ,","place":["USA"]}]}],"member":"286","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"2026011921154401100_ejhfhft052-bib-0001","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure","volume":"20","author":"Packer","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2026011921154401100_ejhfhft052-bib-0002","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1388-9842(00)00102-1","article-title":"Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies","volume":"2","author":"Swedberg","year":"2000","journal-title":"Eur J Heart Fail"},{"key":"2026011921154401100_ejhfhft052-bib-0003","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/17.suppl_B.21","article-title":"Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease","volume":"17(Suppl B)","author":"Packer","year":"1996","journal-title":"Eur Heart J"},{"key":"2026011921154401100_ejhfhft052-bib-0004","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/eurjhf\/hfr093","article-title":"CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin\u2013angiotensin\u2013aldosterone system the cornerstone of therapy for systolic heart failure","volume":"13","author":"McMurray","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026011921154401100_ejhfhft052-bib-0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1388-9842(01)00144-1","article-title":"Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure","volume":"3","author":"Shibata","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"2026011921154401100_ejhfhft052-bib-0006","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0024-3205(81)90370-2","article-title":"A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats","volume":"28","author":"de Bold","year":"1981","journal-title":"Life Sci"},{"key":"2026011921154401100_ejhfhft052-bib-0007","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1172\/JCI114385","article-title":"Role of endogenous atrial natriuretic factor in acute congestive heart failure","volume":"84","author":"Lee","year":"1989","journal-title":"J Clin Invest"},{"key":"2026011921154401100_ejhfhft052-bib-0008","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/01.CIR.89.5.2232","article-title":"Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors","volume":"89","author":"Wada","year":"1994","journal-title":"Circulation"},{"key":"2026011921154401100_ejhfhft052-bib-0009","first-page":"R936","article-title":"Clearance receptor-mediated control of atrial natriuretic factor in experimental congestive heart failure","volume":"266","author":"Brandt","year":"1994","journal-title":"Am J Physiol"},{"key":"2026011921154401100_ejhfhft052-bib-0010","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","author":"Mangiafico","year":"2012","journal-title":"Eur Heart J"},{"key":"2026011921154401100_ejhfhft052-bib-0011","first-page":"55","article-title":"Significance of atrial natriuretic factor in chronic heart failure","volume":"40","author":"McMurray","year":"1988","journal-title":"Br J Hosp Med"},{"key":"2026011921154401100_ejhfhft052-bib-0012","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(89)90714-9","article-title":"Effects of UK 69 578: a novel atriopeptidase inhibitor","volume":"2","author":"Northridge","year":"1989","journal-title":"Lancet"},{"key":"2026011921154401100_ejhfhft052-bib-0013","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/01.CIR.86.4.1089","article-title":"Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure","volume":"86","author":"M\u00fcnzel","year":"1992","journal-title":"Circulation"},{"key":"2026011921154401100_ejhfhft052-bib-0014","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1053\/euhj.1998.1201","article-title":"Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition","volume":"19","author":"Newby","year":"1998","journal-title":"Eur Heart J"},{"key":"2026011921154401100_ejhfhft052-bib-0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0735-1097(00)00741-5","article-title":"The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure","volume":"36","author":"McClean","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026011921154401100_ejhfhft052-bib-0016","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet"},{"key":"2026011921154401100_ejhfhft052-bib-0017","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2026011921154401100_ejhfhft052-bib-0018","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"2026011921154401100_ejhfhft052-bib-0019","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","article-title":"Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema","volume":"153","author":"Fryer","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2026011921154401100_ejhfhft052-bib-0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor\u2013neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2026011921154401100_ejhfhft052-bib-0021","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"2026011921154401100_ejhfhft052-bib-0022","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/FJC.0b013e318210fc7e","article-title":"Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat","volume":"57","author":"Hegde","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026011921154401100_ejhfhft052-bib-0023","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026011921154401100_ejhfhft052-bib-0024","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"The EuroQol Group. EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"2026011921154401100_ejhfhft052-bib-0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"2026011921154401100_ejhfhft052-bib-0026","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/00005344-200211000-00018","article-title":"2002. Pharmacokinetics of multiple doses of valsartan in patients with heart failure","volume":"40","author":"Prasad","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026011921154401100_ejhfhft052-bib-0027","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ejheart.2008.07.014","article-title":"State of the art: using natriuretic peptide levels in clinical practice","volume":"10","author":"Maisel","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026011921154401100_ejhfhft052-bib-0028","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/eurjhf\/hfn046","article-title":"CORONA Study Group. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide","volume":"11","author":"Wedel","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026011921154401100_ejhfhft052-bib-0029","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"2026011921154401100_ejhfhft052-bib-0030","first-page":"1429","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"2026011921154401100_ejhfhft052-bib-0031","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"2026011921154401100_ejhfhft052-bib-0032","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"2026011921154401100_ejhfhft052-bib-0033","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/euhj.1997.0839","article-title":"Clinical outcome with enalapril in symptomatic chronic heart failure;a dose comparison. The NETWORK Investigators","volume":"19","year":"1998","journal-title":"Eur Heart J"},{"key":"2026011921154401100_ejhfhft052-bib-0034","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/S0735-1097(00)01025-1","article-title":"Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril:a multicenter study. High Enalapril Dose Study Group","volume":"36","author":"Nanas","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026011921154401100_ejhfhft052-bib-0035","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ejheart.2003.12.019","article-title":"CARMEN investigators and co-ordinators. Tolerability of carvedilol and ACE-inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)","volume":"6","author":"Komajda","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026011921154401100_ejhfhft052-bib-0036","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","article-title":"CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III","volume":"112","author":"Willenheimer","year":"2005","journal-title":"Circulation"},{"key":"2026011921154401100_ejhfhft052-bib-0037","first-page":"187","article-title":"Enalapril in the treatment of mild-to-moderate heart failure in general medical practice: a prospective and multicentre study concerning 17,546 patients","volume":"50","author":"Messner Pellenc","year":"1995","journal-title":"Acta Cardiol"},{"key":"2026011921154401100_ejhfhft052-bib-0038","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2026011921154401100_ejhfhft052-bib-0039","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2026011921154401100_ejhfhft052-bib-0040","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"2026011921154401100_ejhfhft052-bib-0041","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2026011921154401100_ejhfhft052-bib-0042","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026011921154401100_ejhfhft052-bib-0043","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1161\/01.RES.65.3.640","article-title":"Enkephalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary sodium excretion in rats with reduced renal mass","volume":"65","author":"Lafferty","year":"1989","journal-title":"Circ Res"},{"key":"2026011921154401100_ejhfhft052-bib-0044","doi-asserted-by":"crossref","first-page":"H1206","DOI":"10.1152\/ajpheart.00085.2003","article-title":"Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study","volume":"285","author":"van der Zander","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026011921154401100_ejhfhft052-bib-0045","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/BF00637742","article-title":"Effect of human atrial natriuretic peptide on blood glucose concentrations and hormone stimulation during insulin-induced hypoglycaemia in healthy man","volume":"36","author":"Jungmann","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"2026011921154401100_ejhfhft052-bib-0046","doi-asserted-by":"crossref","first-page":"e1001112","DOI":"10.1371\/journal.pmed.1001112","article-title":"Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes:evidence of causal association from population studies","volume":"8","author":"Pfister","year":"2011","journal-title":"PLoS Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhft052","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhft052","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hft052","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hft052","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/9\/1062\/66441501\/eurjhf_15_9_1062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/9\/1062\/66441501\/eurjhf_15_9_1062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:19:14Z","timestamp":1768875554000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/15\/9\/1062\/8428745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,1]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,1,27]]},"published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hft052","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,9]]},"published":{"date-parts":[[2013,9,1]]}}}